X

Trial Profile

A Phase II Randomized Study of Chemo-Anticoagulation (Gemcitabine-Dalteparin) Versus Chemotherapy Alone (Gemcitabine) for Locally Advanced and Metastatic Pancreatic Adenocarcinoma [FRAGEM].

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalteparin sodium (Primary) ; Gemcitabine (Primary)
Indications Pulmonary embolism; Venous thromboembolism
Focus Biomarker; Therapeutic Use
Acronyms FRAGEM

Most Recent Events

17 Nov 2011 Results published in the European Journal of Cancer.
09 Apr 2010 Results from a substudy that investigated the effects of treatment on circulating-tissue factor antigen levels published in Blood Coagulation and Fibrinolysis
20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com